Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.430
-0.020 (-1.38%)
Dec 5, 2025, 4:00 PM EST - Market closed
Actinium Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Other Revenue | 0.09 | - | 0.08 | 1.03 | 1.14 | - | |
| Revenue | 0.09 | - | 0.08 | 1.03 | 1.14 | - | |
| Revenue Growth (YoY) | 11.11% | - | -92.14% | -9.96% | - | - | |
| Gross Profit | 0.09 | - | 0.08 | 1.03 | 1.14 | - | |
| Selling, General & Admin | 15.79 | 12.08 | 13.33 | 12 | 8.08 | 6.31 | |
| Research & Development | 21.64 | 30.05 | 38.67 | 23.14 | 18.03 | 16.09 | |
| Operating Expenses | 37.43 | 42.12 | 52 | 35.13 | 26.11 | 22.39 | |
| Operating Income | -37.34 | -42.12 | -51.92 | -34.1 | -24.96 | -22.39 | |
| Interest & Investment Income | 2.74 | 3.88 | 3.1 | 1.09 | 0.19 | 0.18 | |
| Pretax Income | -34.6 | -38.24 | -48.82 | -33.02 | -24.77 | -22.22 | |
| Net Income | -34.6 | -38.24 | -48.82 | -33.02 | -24.77 | -22.22 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0 | |
| Net Income to Common | -34.6 | -38.24 | -48.82 | -33.02 | -24.77 | -22.22 | |
| Shares Outstanding (Basic) | 31 | 30 | 27 | 24 | 21 | 12 | |
| Shares Outstanding (Diluted) | 31 | 30 | 27 | 24 | 21 | 12 | |
| Shares Change (YoY) | 7.11% | 13.03% | 10.20% | 17.37% | 69.51% | 143.87% | |
| EPS (Basic) | -1.11 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | |
| EPS (Diluted) | -1.11 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | |
| Free Cash Flow | -25.04 | -33.08 | -47.49 | 8.28 | -21 | -21.87 | |
| Free Cash Flow Per Share | -0.80 | -1.10 | -1.78 | 0.34 | -1.02 | -1.80 | |
| Gross Margin | 100.00% | - | 100.00% | 100.00% | 100.00% | - | |
| Operating Margin | -41486.67% | - | -64098.76% | -3311.07% | -2182.17% | - | |
| Profit Margin | -38443.33% | - | -60269.14% | -3205.53% | -2165.56% | - | |
| Free Cash Flow Margin | -27824.44% | - | -58627.16% | 803.69% | -1835.58% | - | |
| EBITDA | -37.12 | -41.91 | -51.71 | -33.9 | -24.78 | -22.26 | |
| D&A For EBITDA | 0.22 | 0.21 | 0.21 | 0.21 | 0.19 | 0.14 | |
| EBIT | -37.34 | -42.12 | -51.92 | -34.1 | -24.96 | -22.39 | |
| Revenue as Reported | 0.09 | - | 0.08 | 1.03 | 1.14 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.